World Journal of Cardiology

Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.4330/wjc.v7.i3.134

World J Cardiol 2015 March 26; 7(3): 134-143
ISSN 1949-8462 (online)
© 2015 Baishideng Publishing Group Inc. All rights reserved.

REVIEW

Role of *Helicobacter pylori* infection in pathogenesis of atherosclerosis

Rajesh Vijayvergiya, Ramalingam Vadivelu

Rajesh Vijayvergiya, Ramalingam Vadivelu, Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
Author contributions: Both the authors have contributed equally to this review article; Vijayvergiya R has done literature search, critical review and analysis of the literature and a revision of the manuscript; and Vadivelu R has performed literature search and review, articles extraction, writing of first draft of the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Rajesh Vijayvergiya, MD, DM, FSCAI, FISES, FACC, Additional Professor, Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. rajeshvijay999@hotmail.com
Telephone: +91-172-2756518
Fax: +91-172-2744401
Received: June 24, 2014
Peer-review started: June 24, 2014
First decision: June 24, 2014
Revised: October 4, 2014
Accepted: November 27, 2014
Article in press: December 1, 2014
Published online: March 26, 2015

Abstract

Though a century old hypothesis, infection as a cause for atherosclerosis is still a debatable issue. Epidemiological and clinical studies had shown a possible association but inhomogeneity in the study population and study methods along with potential confounders have yielded conflicting results. Infection triggers a chronic inflammatory state which along with other mechanisms such as dyslipidemia, hyper-homocysteinemia, hypercoagulability, impaired glucose metabolism and endothelial dysfunction, contribute in pathogenesis of atherosclerosis. Studies have shown a positive relations between Cytotoxic associated gene-A positive strains of *Helicobacter pylori* and vascular diseases such as coronary artery disease and stroke. Infection mediated genetic modulation is a new emerging theory in this regard. Further large scale studies on infection and atherosclerosis focusing on multiple pathogenetic mechanisms may help in refining our knowledge in this aspect.

Key words: Atherosclerosis; Coronary artery disease; *Helicobacter pylori* ; Infection; Stroke

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Though a century old hypothesis, infection as a cause of atherosclerosis is still a debatable issue. Clinical and epidemiological studies had shown a possible association, however in-homogeneity in the study population and methodology has yielded conflicting results. We performed a literature search on MEDLINE electronic database using keywords such as *Helicobacter pylori* (*H. pylori*), infection, atherosclerosis, coronary artery disease, myocardial infarction, stroke, cerebro-vascular disease and peripheral arterial disease using MeSH terms, to review this subject. The association between *H. pylori* and atherosclerosis is not strong and a causal role is not yet established. Large scale studies on infection and atherosclerosis focusing on multiple pathogenetic mechanisms may help in refining our knowledge in this aspect.

Vijayvergiya R, Vadivelu R. Role of *Helicobacter pylori* infection in pathogenesis of atherosclerosis. *World J Cardiol* 2015; 7(3): 134-143 Available from: URL: http://www.wjgnet.com/1949-8462/full/v7/i3/134.htm DOI: http://dx.doi.org/10.4330/wjc.v7.i3.134

INTRODUCTION

Though a century old hypothesis, infection is still debated as a cause of atherosclerosis[1]. Infection triggers a chronic inflammatory state which along with other mechanisms such as dyslipidemia, hyperhomocysteinaemia, hypercoagulability, impaired glucose metabolism and endothelial dysfunction contribute in pathogenesis of atherosclerosis. Studies have shown a positive relations between Cytotoxic associated gene-A (Cag-A) positive *Helicobacter pylori* (*H. pylori*) strains with vascular diseases such as coronary artery disease (CAD) and stroke. Infection mediated genetic modulation is a new emerging theory in this regard. Minick and Fabricant's work on infection and atherosclerosis in animal model had made the ground for revolutionary research in this field[2,3]. Chronic infection triggers T1 Helper cell (Th1) mediated inflammatory reaction, which plays a crucial role in atherosclerosis. Markers of infection and inflammation were also studied as the risk factors for atherosclerosis[4-6]. An association between infection and atherosclerosis was established following detection of infectious agents from arterial vessels, positive immunehistochemistry studies, detection of microbial DNA sequences in atherosclerotic plaques by PCR method, positive serological response with higher titres in infected patients, and a positive correlation of infection with atherosclerotic burden and dyslipidaemia[7-23]. The microbial agents that have been implicated in the etiopathogenesis of atherosclerosis are presented in Table 1, Figure 1.

This review has been divided into two parts. Part Ⅰ elucidates different mechanisms of *H. pylori* related atherosclerosis and relevant studies. Part Ⅱ reviews the literature about *H. pylori* association with atherosclerotic diseases such as CAD, stroke and peripheral arterial disease (PAD).

MECHANISMS OF *H. PYLORI* RELATED ATHEROSCLEROSIS

Development of CAD in patients without conventional risk factors suggests a possible role of an additional unexplored mechanism. The evolution of atherosclerosis in the background of chronic inflammatory milieu involves multiple pathways (Table 2, Figure 1). Some of these pathways will be discussed in following section.

H. pylori and endothelial dysfunction

Infection related chronic vascular inflammation can result in endothelial dysfunction. Tousoulis *et al*[24] first proposed an inflammatory mechanism for endothelial dysfunction. C-reactive protein (CRP) and inflammatory adhesion molecule such as intracellular adhesion molecule-1 (ICAM-1) are elevated in patients with *H. pylori* infection, suggesting a possible link between infection and endothelial dysfunction[25].

Table 1 Microbial agents associated with atherosclerosis

Bacteria	Viruses
Chlamydia pneumonia	H simplex virus type 1 and 2
Helicobacter pylori	Cytomegalovirus
Helicobacter cinaedi	Epstein- Barr virus
Hemophilus influenza	
Mycoplasma pneumonia	

Chronic infection triggers release of inflammatory cytokines such as interleukin (IL)-1, IL-6 and tumor necrosis factor-α (TNF-α), which affects microvascular vasomotor functions, resulting into vasoconstriction and endothelial dysfunction. Coskun *et al*[26] studied a possible relation between *H. pylori* infection in children and endothelial dysfunction as a precursor for future atherosclerosis. There was no significant association between *H. pylori* seropositivity and CRP levels with flow mediated vasodilation. Another evidence is about increase prevalence of slow flow in the major epicardial coronary arteries in patients with *H. pylori* infection[27]. The possible mechanism of slow flow was endothelial dysfunction secondary to raised homocysteine levels. *H. pylori* infection causes malabsorption of vitamin B12 and folic acid and thus increases serum homocysteine levels. Evrengul *et al*[27] reported a mean TIMI frame count of coronary flow as 46.3 ± 8.7 and 24.3 ± 2.9 in patients with and without *H. pylori* infection, respectively. An association between *H. pylori* infection and functional vascular disorders such as cardiac syndrome-X, migraine and primary Reynaud phenomenon provides evidence about its role in endothelial dysfunction and atherosclerosis[28-32].

Chronic inflammation

Presence of chronic, persistent inflammation provides a vital clue for infectious theory of CAD. Chronic *H. pylori* infection induces a pro-inflammatory state, resulting into an increase in cytokines levels such as TNF-α, Interleukins (IL-1, IL-6, IL-8), gamma interferon, coagulant factors - fibrinogen, thrombin and soluble adhesion molecules such as intercellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (VCAM-1)[33-35]. Eradication of *H. pylori* infection by use of antibiotics leads to reduction in cytokines levels[34,36]. These evidences suggest that *H. pylori* induced inflammatory cascade plays an active role in atherosclerosis. Activated T lymphocytes and macrophages following cytokines release induce proliferation of smooth muscle cells and extracellular matrix, which plays a crucial role in pathogenesis of atherosclerosis. It also stimulates metalloproteinases production, which causes rupture of atheroma cap and leads to acute coronary syndromes. However, a large population based study failed to support the association between *H. pylori* and increased inflammatory cytokines[37].

Recent research has unveiled novel molecular



Figure 1 Theories of infection related atherosclerosis.

Table 2 Mechanisms of *Helicobacter pylori* related atherosclerosis

Induction of inflammatory response secondary to chronic infectious state
Endothelial damage
Chronic low grade activation of coagulation cascade
Dysregulation of lipid metabolism resulting in increased total cholesterol and triglyceride levels and reduced high density lipoprotein levels
Hyperhomocysteinaemia

While the proponents support the possible association[52,70,104], the opponents refute this hypothesis[46,71,105].

mechanisms of *H. pylori* mediated inflammation[38-41]. *H. pylori* infection exerts an immune-inflammatory reaction by activating cyclooxygenase enzyme-2 (COX-2), which causes increase production of prostaglandin (PGE_2) and nitric oxide (NO). *H. pylori* cell wall lipopolysaccharide (LPS) triggers toll-like receptor-4, which activates various secondary mediators such as mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK) and p38 kinase resulting in enhanced stimulation of *NOS* and *COX-2* gene expression[38,39]. LPS-induced activation of MAPK cascade is also associated with epidermal growth factor receptor (EGFR) transactivation which is a key protein regulating cellular proliferation, differentiation, migration and modulation of apoptosis[41]. Gherlin, a peptide hormone activates NO synthase, thereby inhibiting *H. pylori* LPS induced activation of COX-2 and other inflammatory pathways[40].

H. pylori and hyper-homocysteinaemia

H. pylori causes atrophic gastritis, which is associated with malabsorption of vitamin B12 and folic acid. Deficiency of these vitamins causes hyper-homocysteinaemia due to interruption of re-methylation pathway[42-45]. Hence, it may have a role in the pathogenesis of premature atherosclerosis[45]. In a study by Kutluana *et al*[45], carotid intima media thickness was found to be higher in patients with *H. pylori* related atrophic gastritis. In this study, *H. pylori* positive patients had significantly higher homocysteine levels compared to controls (14.17 ± 9.24 μmol/L *vs* 9.81 ± 3.42 μmol/L, $P = 0.01$). Senmaru *et al*[46] reported a higher prevalence of CAD in atrophic gastritis (5.8% *vs* 2.8%). Torisu *et al*[47] had shown an association between increased pulse wave velocity, a preclinical marker of atherosclerosis with atrophic gastritis. Apart from hyper-homocysteinaemia, other mechanisms are reduced ghrelin levels and induction of chronic pro-inflammatory cascade resulting into endothelial damage[46,47]. However, Bloemenkamp *et al*[48] did not support the hypothesis about *H. pylori* infection induced hyper-homocysteinemia and atherosclerosis.

H. pylori and dyslipidemia

H. pylori infection is associated with lower HDL cholesterol (HDL-C) and higher total cholesterol (TC), LDL cholesterol (LDL-C) and triglyceride levels. Higher apolipoprotein-B and lower apolipoprotein-A (apo-A) levels were also reported[11]. Murray *et al*[49] demonstrated that women with *H. pylori* infection had lower HDL-C ($P = 0.006$). Another study had also shown significantly lower HDL-C levels in

infected patients[11]. Niemelä *et al*[50] and Laurila *et al*[22] reported an increase triglyceride levels in *H. pylori* positive patients. These alterations in lipid homeostasis proved to be significant even after adjusting co-variables such as socioeconomic class, body weight, age and diabetic status[22,51]. de Luis *et al*[52] showed that eradication of *H. pylori* decreases apo-A and increases HDL-C. Other studies had also shown reduction in TC, LDL-C levels and increase in HDL-C, apo-AI and apo-AII levels following *H. pylori* eradication[53-55]. However, this association was not supported by few other authors[56-59].

H. pylori, impaired glucose metabolism and metabolic syndrome

Gillum *et al*[60] reported a significant association of *H. pylori* seropositivity with CAD in diabetic males. de Luis *et al*[51] showed that CAD and cerebrovascular diseases were significantly more seen in *H. pylori* infected diabetic patients. Yoshikawa *et al*[61] suggested that *H. pylori* seropositivity increases brachial-ankle pulse wave velocity, a marker of atherosclerosis, in patients with impaired glucose metabolism. Aydemir *et al*[62] reported that *H. pylori* positive subjects had higher homeostatic model assessment-insulin resistance (HOMA-IR) levels (2.56 ± 1.54 *vs* 1.73 ± 1.1, $P < 0.05$), a surrogate of insulin resistance, as compared to *H. pylori* negative controls. Aslan *et al*[63] had shown that paraoxanase, a marker of oxidative stress is well correlated with HOMA-IR levels and is significantly elevated in *H. pylori* positive patients. Regarding role of *H. pylori* eradication therapy in improvement of glucose tolerance, Gen *et al*[64] reported that HOMA-IR level significantly reduced after successful therapy, whereas Park *et al*[65] did not show any significant reduction. Polyzos *et al*[66] in his systematic review concluded that available evidences indicate a potential association between *H. pylori* infection and insulin resistance. Gunji *et al*[67] reported that *H. pylori* infection was significantly and independently associated with metabolic syndrome. A recent study by Ando *et al*[68] revealed that eradication of *H. pylori* increases circulating adiponectin levels and might be helpful in prevention of metabolic syndrome. Naja *et al*[69] suggested no association between *H. pylori* infection and metabolic syndrome or impaired glucose tolerance.

H. pylori, hypertension and arterial stiffness

Migneco *et al*[70] demonstrated a significant reduction in blood pressure after eradication of *H. pylori* in hypertensive subjects. The possible association of *H. pylori* with arterial stiffness was initially reported by Adachi and Yoshikawa. Adachi *et al*[71] reported that carotid pulse wave velocity was higher in seropositive subjects. Yoshikawa *et al*[61] similarly reported a higher brachial-ankle pulse wave velocity in seropositive patients with impaired glucose metabolism. The possible association of *H. pylori* and arterial stiffness tends to be more in younger subjects, whereas in the elderly arterial stiffness is more often due to aging[72]. Honda *et al*[73] demonstrated that *H. pylori* infection did not affect the age related progression of arteriosclerosis over a 4 years follow-up period.

EVIDENCE OF ASSOCIATION BETWEEN *H. PYLORI* AND ATHEROSCLEROSIS

H. pylori and CAD

Demonstration of an association between *H. pylori* and CAD is always challenging. Both conditions are more prevalent in the population, increases with age and are related to socioeconomic status. The following section reviews the evidence of *H. pylori* association with CAD.

Numerous studies have shown that CAD patients have a higher prevalence of *H. pylori* infection[74-77]. Vijayvergiya *et al*[77] demonstrated that CAD patients had higher IgG seropositivity as compared to controls (42% *vs* 23%, $P = 0.06$). Franceschi *et al*[78] found that *H. pylori* Cag-A was significantly associated with acute coronary events (OR = 1.34; 95%CI: 1.15-1.58, $P = 0.0003$). Niemelä *et al*[50] showed that the association between CAD and *H. pylori* infection was not strong. A meta-analysis revealed that there is a little association between *H. pylori* infection and stroke, but the strength of association was greater for Cag-A positive strains[79]. *H. pylori* was shown to be associated with premature CAD even in patients without conventional cardiovascular risk factors[80,81]. A number of studies had shown a negative association between *H. pylori* and CAD which include serological[82,83] and histological studies[84-86]. A negative association is even reported in long term follow-up studies[87]. The Australian Busselton health study comprising of 1612 healthy subjects demonstrated negative association between infection and CAD or stroke[88]. Danesh *et al*[89] in his meta-analysis of five prospective studies reported no significant association of *H. pylori* infection with CAD (RR = 1.13). Association of *H. pylori* infection and outcome of CAD treatment had also been studied. Schiele *et al*[90] found that *H. pylori* infection was not a risk factor for restenosis after percutaneous coronary angioplasty. Limnell *et al*[91] had shown an inverse relationship between *H. pylori* infection and coronary bypass graft occlusion. Results from Caerphilly heart disease study suggested that Cag-A seropositivity had no relations with CAD or CAD related mortality[92].

H. pylori has been associated with cardiac syndrome X, *i.e.*, angina pectoris with normal epicardial coronaries[28-30]. The proposed mechanism is chronic endothelial dysfunction. Eskandrian *et al*[28] reported a higher prevalence of *H. pylori* positivity in syndrome X patients compared to controls (95% *vs* 47.5%). Patients with syndrome X were found to be more commonly associated with *H. pylori* Cag-A positivity and elevated IL-1 and TNF-α[93]. Lanza *et al*[94] has

also described association of inflammation, infectious burden and vascular dysfunction. Assadi *et al*[30] reported 15% of patients with syndrome X had urea breath test (UBT) positivity for *H. pylori* while none of the patients with chronic stable angina or controls had UBT positivity.

H. pylori and acute myocardial infarction

H. pylori induced inflammatory reaction is possibly responsible for plaque instability and platelet aggregation in acute coronary syndrome patients. Danesh *et al*[95] demonstrated a higher prevalence of *H. pylori* infection (42% *vs* 24%, OR = 1.75) in young acute myocardial infarction (AMI) survivors. Alkout *et al*[96] showed a higher titre of *H. pylori* IgG titre in patients who died of AMI (151 ng/mL *vs* 88 ng/mL, p= 0.034). Kahan *et al*[97] reported a higher prevalence of *H. pylori* seropositivity in recent myocardial infarction patients as compared to controls (68% *vs* 53%, OR = 1.36). This remained significant even after adjusting for other CAD risk factors like age, sex, smoking and hypertension. Kinjo *et al*[98] suggested that *H. pylori* infection was significantly associated with AMI in younger patients (age < 55 years, OR = 2.7) but not in those with age of > 55 years. Frazer *et al* showed a higher prevalence of *H. pylori* infection in AMI patients compared to control (41.6% *vs* 34.5%; $P = 0.038$)[99].

Similar to CAD, negative associations is also been reported between *H. pylori* and myocardial infarction. Zhu *et al*[100] hypothesised that *H. pylori* infection could not lead to CAD or myocardial infarction. Murray *et al*[101] had shown a negative association between *H. pylori* and risk for myocardial infarction. Pellicano *et al*[102] reported a negative association between cytotoxic *H. pylori* strains and myocardial infarction, with insignificant anti-Cag-A antibody seropositivtiy between cases and controls (33.8% *vs* 26.8%).

H. pylori Cag-A positivity - Is the risk greater?

Cag-A positivity has raised a curiosity in the infectious theory of atherosclerosis. Several studies had shown a significant relationship between Cag-A strain and CAD or stroke. Carriers of Cag-A positive strains had a higher risk for stroke (OR = 2.99) and carotid plaque instability (OR = 8.42)[103]. De Bastiani *et al*[104] showed increased prevalence of Cag-A seropositivity and ischemic stroke. Rasmi *et al*[93] reported a positive relation between Cag-A seropositivity and cardiac syndrome-X. Huang *et al*[105] revealed that Cag-A positive strains enhanced atherosclerosis in CAD patients by modifying oxidised LDL levels and high sensitive C-reactive protein (hsCRP) levels. Kowalski[36] showed that Cag-A positivity was significantly associated with greater coronary artery lumen loss and restenosis after percutaneous coronary artery stenting. He also demonstrated that *H. pylori* eradication significantly attenuate reduction in coronary artery lumen after coronary artery stenting[36]. But various authors had denied the excess risk of Cag-A positive strains with atherosclerosis. Koenig *et al*[106] demonstrated a similar prevalence of Cag-A seropositivity in CAD patients and healthy subjects. Whincup *et al*[107] in his prospective study comprising of 505 patients and 1025 healthy subjects had clearly shown that there was no significant association of seropositivity with CAD. Murray *et al*[101] reported negative association between the virulent *H. pylori* Cag-A strains and acute myocardial infarction.

H. pylori and stroke

By catalysing atherosclerotic pathways, *H. pylori* infection may be a risk factor for ischemic stroke. Single infectious agent is weakly linked to stroke but cumulative chronic infectious exposures, or "infectious burden", have been associated with the risk of stroke. The adjusted hazard ratio demonstrating the risk of association between *H. pylori* and stroke was 1.13, whereas that of infectious burden and stroke was 1.39[108]. The possible mechanisms include macrophage activated plaque destabilization, increased expression of various adhesion molecules and inflammatory cytokines, localized hypercoagulability, altered gene expression, and a molecular mimicry. Markus *et al*[109] found a higher prevalence of *H. pylori* seropositivity in stroke cases compared to controls. There was an association between *H. pylori* infection and large vessel disease and lacunar stroke irrespective of other confounding factors. Another study by Grau *et al*[110] demonstrated an association between *H. pylori* seropositivity and ischemic stroke. Elkind *et al*[111] suggested that that chronic infectious burden results in increase carotid plaque thickness and stroke. A retrospective study reported higher incidence of ischemic stroke in patients with *H. pylori* infection than in non-infected group (14.8 *vs* 8.45 per 1000 person years)[112]. Diomedi *et al*[113] showed that Cag-A positive *H. pylori* infection was associated with poorer short term clinical outcomes and greater carotid intima media thickness in stroke patients. Increased risk of stroke in Cag-A positive *H. pylori* patients may be due to enhanced plaque vulnerability[103,114]. In one of the studies, the positive correlation between *H. pylori* and stroke was confounded by socioeconomic class[115]. A study on chronic bacterial infection and stroke demonstrated that elevated anti- *H. pylori* antibody was not significantly associated with ischemic stroke[116].

H. pylori and peripheral arterial disease

Studies about association of *H. pylori* infection with peripheral arterial disease (PAD) are limited. Bloemenkamp *et al*[117] demonstrated infection as a novel risk factor for PAD in young women. A case control study on infection and PAD in young women suggested that *H. pylori* infection was positively correlated with PAD only in those with high CRP levels[118]. Sawayama *et al*[119] reported a significantly higher prevalence of *H.*

pylori infection in PAD cases than in controls (79.7% *vs* 44.8%; $P < 0.01$).

CONCLUSION

Overall the association between *H. pylori* and CAD is not strong and a causal role is yet to be established. Future studies on larger scale may possibly establish a stronger link between the two. If it gets established, there can be drastic reduction in burden of CAD by managing *H. pylori* infection. Proponents of infectious theory will have a real challenge in the years to come because establishing a definite causal role of *H. pylori* in CAD will be a nightmare due to the existence of numerous confounding factors. Opponents may continue to criticise the infectious theory of CAD because of lack of strong scientific evidence.

REFERENCES

1 **Frothingham C**. The relation between acute infectious diseases and arterial lesions. *Arch Intern Med* 1911; **8**: 153 [DOI: 10.1001/archinte.1911.00060080033004]

2 **Minick CR**, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with a herpesvirus. *Am J Pathol* 1979; **96**: 673-706 [PMID: 382868]

3 **Fabricant CG**, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis in chickens. *Fed Proc* 1983; **42**: 2476-2479 [PMID: 6840298]

4 **Benagiano M**, Azzurri A, Ciervo A, Amedei A, Tamburini C, Ferrari M, Telford JL, Baldari CT, Romagnani S, Cassone A, D'Elios MM, Del Prete G. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. *Proc Natl Acad Sci USA* 2003; **100**: 6658-6663 [PMID: 12740434 DOI: 10.1073/pnas.1135726100]

5 **Hansson GK**, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. *Annu Rev Pathol* 2006; **1**: 297-329 [PMID: 18039117 DOI: 10.1146/annurev.pathol.1.110304.100100]

6 **Lindsberg PJ**, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. *Stroke* 2003; **34**: 2518-2532 [PMID: 14500942 DOI: 10.1161/01.STR.0000089015.51603.CC]

7 **Ameriso SF**, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. *Stroke* 2001; **32**: 385-391 [PMID: 11157171 DOI: 10.1161/01.STR.32.2.385]

8 **Farsak B**, Yildirir A, Akyön Y, Pinar A, Oç M, Böke E, Kes S, Tokgözoğlu L. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. *J Clin Microbiol* 2000; **38**: 4408-4411 [PMID: 11101572]

9 **Adiloglu AK**, Ocal A, Can R, Duver H, Yavuz T, Aridogan BC. Detection of Helicobacter pylori and Chlamydia pneumoniae DNA in human coronary arteries and evaluation of the results with serologic evidence of inflammation. *Saudi Med J* 2005; **26**: 1068-1074 [PMID: 16047055]

10 **Kaplan M**, Yavuz SS, Cinar B, Koksal V, Kut MS, Yapici F, Gercekoglu H, Demirtas MM. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. *Int J Infect Dis* 2006; **10**: 116-123 [PMID: 16183317 DOI: 10.1016/j.ijid.2004.10.008]

11 **Hoffmeister A**, Rothenbacher D, Bode G, Persson K, März W, Nauck MA, Brenner H, Hombach V, Koenig W. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. *Arterioscler Thromb Vasc Biol* 2001; **21**: 427-432 [PMID: 11231924 DOI: 10.1161/01.ATV.21.3.427]

12 **Epstein SE**, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. *Circulation* 1999; **100**: e20-e28 [PMID: 10421626 DOI: 10.1161/01.CIR.100.4.e20]

13 **Epstein SE**, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. *Arterioscler Thromb Vasc Biol* 2000; **20**: 1417-1420 [PMID: 10845851 DOI: 10.1161/01.ATV.20.6.1417]

14 **Espinola-Klein C**, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, Meyer J. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. *Circulation* 2002; **105**: 15-21 [PMID: 11772870 DOI: 10.1161/hc0102.101362]

15 **Espinola-Klein C**, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of infectious burden on progression of carotid atherosclerosis. *Stroke* 2002; **33**: 2581-2586 [PMID: 12411646 DOI: 10.1161/01.STR.0000034789.82859.A4]

16 **Blankenberg S**, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, Hafner G, Ossendorf M, Steinhagen K, Meyer J. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. *Circulation* 2001; **103**: 2915-2921 [PMID: 11413080 DOI: 10.1161/01.CIR.103.24.2915]

17 **Rupprecht HJ**, Blankenberg S, Bickel C, Rippin G, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. *Circulation* 2001; **104**: 25-31 [PMID: 11435333 DOI: 10.1161/hc2601.091703]

18 **Saikku P**. Role of Infection in the Pathogenesis of Coronary Artery Disease. *J Interv Cardiol* 1998; **11**: 525-528 [DOI: 10.1111/j.1540-8183.1998.tb00163.x]

19 **Saikku P**, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, Mänttäri M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. *Ann Intern Med* 1992; **116**: 273-278 [PMID: 1733381 DOI: 10.7326/0003-4819-116-4-273]

20 **Körner I**, Blatz R, Wittig I, Pfeiffer D, Rühlmann C. Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions. *Vasa* 1999; **28**: 259-263 [PMID: 10611843 DOI: 10.1024/0301-1526.28.4.259]

21 **Chiu B**, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. *Circulation* 1997; **96**: 2144-2148 [PMID: 9337182 DOI: 10.1161/01.CIR.96.7.2144]

22 **Laurila A**, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. *Atherosclerosis* 1999; **142**: 207-210 [PMID: 9920523 DOI: 10.1016/S0021-9150(98)00194-4]

23 **Kowalski M**, Rees W, Konturek PC, Grove R, Scheffold T, Meixner H, Brunec M, Franz N, Konturek JW, Pieniazek P, Hahn EG, Konturek SJ, Thale J, Warnecke H. Detection of Helicobacter pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina. *Dig Liver Dis* 2002; **34**: 398-402 [PMID: 12132786 DOI: 10.1016/S1590-8658(02)80036-6]

24 **Tousoulis D**, Davies GJ, Asimakopoulos G, Homaei H, Zouridakis E, Ahmed N, Kaski JC. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). *Clin Cardiol* 2001; **24**: 301-304 [PMID: 11303698 DOI: 10.1002/clc.4960240409]

25 **Oshima T**, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y, Yoshizumi M, Kambe M. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. *J Am Coll Cardiol* 2005; **45**: 1219-1222 [PMID: 15837252 DOI: 10.1016/j.jacc.2005.01.019]

26 **Coskun S**, Kasirga E, Yilmaz O, Bayindir P, Akil I, Yuksel H, Polat M, Sanlidag T. Is Helicobacter pylori related to endothelial dysfunction during childhood? *Pediatr Int* 2008; **50**: 150-153 [PMID: 18353048 DOI: 10.1111/j.1442-200X.2008.02542.x]

27 **Evrengul H**, Tanriverdi H, Kuru O, Enli Y, Yuksel D, Kilic A, Kaftan A, Kirac S, Kilic M. Elevated homocysteine levels in patients with slow coronary flow: relationship with Helicobacter pylori infection. *Helicobacter* 2007; **12**: 298-305 [PMID: 17669101 DOI:

10.1111/j.1523-5378.2007.00505.x]
28 **Eskandarian R**, Malek M, Mousavi SH, Babaei M. Association of Helicobacter pylori infection with cardiac syndrome X. *Singapore Med J* 2006; **47**: 704-706 [PMID: 16865212]
29 **Nocente R**, Gentiloni N, Cremonini F, Giorgi A, Serricchio M, Santoliquido A, Gasbarrini G, Gasbarrini A. Resolution of syndrome X after eradication of virulent CagA-positive Helicobacter pylori. *South Med J* 2000; **93**: 1022-1023 [PMID: 11147468 DOI: 10.1097/00007611-200010000-00016]
30 **Assadi M**, Saghari M, Ebrahimi A, Reza Pourbehi M, Eftekhari M, Nabipour I, Abbaszadeh M, Nazarahari M, Nasiri M, Assadi S. The relation between Helicobacter pylori infection and cardiac syndrome X: a preliminary study. *Int J Cardiol* 2009; **134**: e124-e125 [PMID: 18501447 DOI: 10.1016/j.ijcard.2008.01.029]
31 **Gasbarrini A**, Massari I, Serricchio M, Tondi P, De Luca A, Franceschi F, Ojetti V, Dal Lago A, Flore R, Santoliquido A, Gasbarrini G, Pola P. Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon. *Dig Dis Sci* 1998; **43**: 1641-1645 [PMID: 9724144 DOI: 10.1023/A: 1018842527111]
32 **Gasbarrini A**, Serricchio M, Tondi P, Gasbarrini G, Pola P. Association of Helicobacter pylori infection with primary Raynaud phenomenon. *Lancet* 1996; **348**: 966-967 [PMID: 8843842 DOI: 10.1016/S0140-6736(05)65386-X]
33 **Russo F**, Jirillo E, Clemente C, Messa C, Chiloiro M, Riezzo G, Amati L, Caradonna L, Di Leo A. Circulating cytokines and gastrin levels in asymptomatic subjects infected by Helicobacter pylori (H. pylori). *Immunopharmacol Immunotoxicol* 2001; **23**: 13-24 [PMID: 11322645 DOI: 10.1081/IPH-100102563]
34 **Consolazio A**, Borgia MC, Ferro D, Iacopini F, Paoluzi OA, Crispino P, Nardi F, Rivera M, Paoluzi P. Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis. *Aliment Pharmacol Ther* 2004; **20**: 289-294 [PMID: 15274665 DOI: 10.1111/j.1365-2036.2004.02074.x]
35 **Maciorkowska E**, Kaczmarski M, Panasiuk A, Kondej-Muszynska K, Kemonai A. Soluble adhesion molecules ICAM-1, VCAM-1, P-selectin in children with Helicobacter pylori infection. *World J Gastroenterol* 2005; **11**: 6745-6750 [PMID: 16425378]
36 **Kowalski M**. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. *J Physiol Pharmacol* 2001; **52**: 3-31 [PMID: 11795863]
37 **Brenner H**, Berg G, Fröhlich M, Boeing H, Koenig W. Chronic infection with Helicobacter pylori does not provoke major systemic inflammation in healthy adults: results from a large population-based study. *Atherosclerosis* 1999; **147**: 399-403 [PMID: 10559526 DOI: 10.1016/S0021-9150(99)00210-5]
38 **Slomiany BL**, Slomiany A. Involvement of p38 MAPK-dependent activator protein (AP-1) activation in modulation of gastric mucosal inflammatory responses to Helicobacter pylori by ghrelin. *Inflammopharmacology* 2013; **21**: 67-78 [PMID: 22669511 DOI: 10.1007/s10787-012-0141-9]
39 **Slomiany BL**, Slomiany A. Induction in gastric mucosal prostaglandin and nitric oxide by Helicobacter pylori is dependent on MAPK/ERK-mediated activation of IKK-β and cPLA2: modulatory effect of ghrelin. *Inflammopharmacology* 2013; **21**: 241-251 [PMID: 23563696 DOI: 10.1007/s10787-013-0169-5]
40 **Slomiany BL**, Slomiany A. Modulation of gastric mucosal inflammatory responses to Helicobacter pylori by ghrelin: Role of cNOS-dependent IKK-β S-nitrosylation in the regulation of COX-2 activation. *Am J Mol Biol* 2012; **2**: 113 [DOI: 10.4236/ajmb.2012.22013]
41 **Slomiany BL**, Slomiany A. Role of epidermal growth factor receptor transactivation in the amplification of Helicobacter pylori-elicited induction in gastric mucosal expression of cyclooxygenase-2 and inducible nitric oxide synthase. *OA Inflamm* 2013; **1**: 1 [DOI: 10.13172/2052-787X-1-1-412]
42 **Sipponen P**, Laxén F, Huotari K, Härkönen M. Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and Helicobacter pylori infection. *Scand J Gastroenterol* 2003; **38**: 1209-1216 [PMID: 14750639 DOI: 10.1080/00365520310007224]
43 **Tamura A**, Fujioka T, Nasu M. Relation of Helicobacter pylori infection to plasma vitamin B12, folic acid, and homocysteine levels in patients who underwent diagnostic coronary arteriography. *Am J Gastroenterol* 2002; **97**: 861-866 [PMID: 12003420 DOI: 10.1111/j.1572-0241.2002.05601.x]
44 **Santarelli L**, Gabrielli M, Cremonini F, Santoliquido A, Candelli M, Nista EC, Pola P, Gasbarrini G, Gasbarrini A. Atrophic gastritis as a cause of hyperhomocysteinaemia. *Aliment Pharmacol Ther* 2004; **19**: 107-111 [PMID: 14687172 DOI: 10.1046/j.1365-2036.2003.01820.x]
45 **Kutluana U**, Simsek I, Akarsu M, Kupelioglu A, Karasu S, Altekin E. Is there a possible relation between atrophic gastritis and premature atherosclerosis? *Helicobacter* 2005; **10**: 623-629 [PMID: 16302990 DOI: 10.1111/j.1523-5378.2005.00356.x]
46 **Senmaru T**, Fukui M, Tanaka M, Kuroda M, Yamazaki M, Oda Y, Naito Y, Hasegawa G, Toda H, Yoshikawa T, Nakamura N. Atrophic gastritis is associated with coronary artery disease. *J Clin Biochem Nutr* 2012; **51**: 39-41 [PMID: 22798711 DOI: 10.3164/jcbn.11-106]
47 **Torisu T**, Takata Y, Ansai T, Matsumoto T, Sonoki K, Soh I, Awano S, Yoshida A, Hamasaki T, Kagiyama S, Nakamichi I, Ohsumi T, Toyoshima K, Nishihara T, Iida M, Takehara T. Possible association of atrophic gastritis and arterial stiffness in healthy middle-aged Japanese. *J Atheroscler Thromb* 2009; **16**: 691-697 [PMID: 19729867 DOI: 10.5551/jat.943]
48 **Bloemenkamp DG**, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, Algra A, Visseren FL, van der Graaf Y. The relation between Helicobacter pylori and atherosclerosis cannot be explained by a high homocysteine concentration. *Eur J Clin Invest* 2002; **32**: 549-555 [PMID: 12190953 DOI: 10.1046/j.1365-2362.2002.01022.x]
49 **Murray LJ**, Bamford KB, O'Reilly DP, McCrum EE, Evans AE. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. *Br Heart J* 1995; **74**: 497-501 [PMID: 8562233 DOI: 10.1136/hrt.74.5.497]
50 **Niemelä S**, Karttunen T, Korhonen T, Läärä E, Karttunen R, Ikäheimo M, Kesäniemi YA. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? *Heart* 1996; **75**: 573-575 [PMID: 8697159 DOI: 10.1136/hrt.75.6.573]
51 **de Luis DA**, Lahera M, Cantón R, Boixeda D, San Román AL, Aller R, de La Calle H. Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. *Diabetes Care* 1998; **21**: 1129-1132 [PMID: 9653607 DOI: 10.2337/diacare.21.7.1129]
52 **de Luis DA**, Garcia Avello A, Lasuncion MA, Aller R, Martin de Argila C, Boixeda de Miquel D, de la Calle H. Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. *Clin Nutr* 1999; **18**: 227-231 [PMID: 10578022 DOI: 10.1016/S0261-5614(99)80074-0]
53 **Majka J**, Róg T, Konturek PC, Konturek SJ, Bielański W, Kowalsky M, Szczudlik A. Influence of chronic Helicobacter pylori infection on ischemic cerebral stroke risk factors. *Med Sci Monit* 2002; **8**: CR675-CR684 [PMID: 12388919]
54 **Kanbay M**, Gür G, Yücel M, Yilmaz U, Boyacioğlu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? *Dig Dis Sci* 2005; **50**: 1228-1231 [PMID: 16047464]
55 **Scharnagl H**, Kist M, Grawitz AB, Koenig W, Wieland H, März W. Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol. *Am J Cardiol* 2004; **93**: 219-220 [PMID: 14715353 DOI: 10.1016/j.amjcard.2003.09.045]
56 **Patel P**, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. *BMJ* 1995; **311**: 711-714 [PMID: 7549683 DOI: 10.1136/bmj.311.7007.711]

57 **Rathbone B**, Martin D, Stephens J, Thompson JR, Samani NJ. Helicobacter pylori seropositivity in subjects with acute myocardial infarction. *Heart* 1996; **76**: 308-311 [PMID: 8983674 DOI: 10.1136/hrt.76.4.308]

58 **Wald NJ**, Law MR, Morris JK, Bagnall AM. Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study. *BMJ* 1997; **315**: 1199-1201 [PMID: 9393222 DOI: 10.1136/bmj.315.7117.1199]

59 **Danesh J**, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. *BMJ* 1998; **316**: 1130-1132 [PMID: 9552950 DOI: 10.1136/bmj.316.7138.1130]

60 **Gillum RF**. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. *J Natl Med Assoc* 2004; **96**: 1470-1476 [PMID: 15586651]

61 **Yoshikawa H**, Aida K, Mori A, Muto S, Fukuda T. Involvement of Helicobacter pylori infection and impaired glucose metabolism in the increase of brachial-ankle pulse wave velocity. *Helicobacter* 2007; **12**: 559-566 [PMID: 17760726 DOI: 10.1111/j.1523-5378.2007.00523.x]

62 **Aydemir S**, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G, Gun BD, Borazan A, Ustundag Y. The effect of Helicobacter pylori on insulin resistance. *Dig Dis Sci* 2005; **50**: 2090-2093 [PMID: 16240220 DOI: 10.1007/s10620-005-3012-z]

63 **Aslan M**, Nazligul Y, Horoz M, Bolukbas C, Bolukbas FF, Gur M, Celik H, Erel O. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. *Atherosclerosis* 2008; **196**: 270-274 [PMID: 17125774 DOI: 10.1016/j.atherosclerosis.2006.10.024]

64 **Gen R**, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. *South Med J* 2010; **103**: 190-196 [PMID: 20134372]

65 **Park SH**, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Kim BI, Keum DK. Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. *J Natl Med Assoc* 2005; **97**: 508-513 [PMID: 15868771]

66 **Polyzos SA**, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. *Helicobacter* 2011; **16**: 79-88 [PMID: 21435084]

67 **Gunji T**, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. *Am J Gastroenterol* 2008; **103**: 3005-3010 [PMID: 19086952 DOI: 10.1111/j.1572-0241.2008.02151.x]

68 **Ando T**, Ishikawa T, Takagi T, Imamoto E, Kishimoto E, Okajima A, Uchiyama K, Handa O, Yagi N, Kokura S, Naito Y, Mizuno S, Asakawa A, Inui A, Yoshikawa T. Impact of Helicobacter pylori eradication on circulating adiponectin in humans. *Helicobacter* 2013; **18**: 158-164 [PMID: 23167259]

69 **Naja F**, Nasreddine L, Hwalla N, Moghames P, Shoaib H, Fatfat M, Sibai A, Gali-Muhtasib H. Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. *Helicobacter* 2012; **17**: 444-451 [PMID: 23066847 DOI: 10.1111/j.1523-5378.2012.00970.x]

70 **Migneco A**, Ojetti V, Specchia L, Franceschi F, Candelli M, Mettimano M, Montebelli R, Savi L, Gasbarrini G. Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. *Helicobacter* 2003; **8**: 585-589 [PMID: 14632672 DOI: 10.1111/j.1523-5378.2003.00180.x]

71 **Adachi K**, Arima N, Takashima T, Miyaoka Y, Yuki M, Ono M, Komazawa Y, Kawamura A, Fujishiro H, Ishihara S, Kinoshita Y. Pulse-wave velocity and cardiovascular risk factors in subjects with Helicobacter pylori infection. *J Gastroenterol Hepatol* 2003; **18**: 771-777 [PMID: 12795747 DOI: 10.1046/j.1440-1746.2003.03059.x]

72 **Prospective Studies Cooperation**. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. *Lancet* 1995; **346**: 1647-1653 [PMID: 8551820]

73 **Honda C**, Adachi K, Arima N, Tanaka S, Yagi J, Morita T, Tanimura T, Furuta K, Kinoshita Y. Helicobacter pylori infection does not accelerate the age-related progression of arteriosclerosis: a 4-year follow-up study. *J Gastroenterol Hepatol* 2008; **23**: e373-e378 [PMID: 18466285 DOI: 10.1111/j.1440-1746.2008.05343.x]

74 **Mendall MA**, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. *Br Heart J* 1994; **71**: 437-439 [PMID: 8011406 DOI: 10.1136/hrt.71.5.437]

75 **Danesh J**. Is there a link between chronic Helicobacter pylori infection and coronary heart disease? *Eur J Surg Suppl* 1998; **(582)**: 27-31 [PMID: 10029361]

76 **Pellicano R**, Mazzarello MG, Morelloni S, Allegri M, Arena V, Ferrari M, Rizzetto M, Ponzetto A. Acute myocardial infarction and Helicobacter pylori seropositivity. *Int J Clin Lab Res* 1999; **29**: 141-144 [PMID: 10784374 DOI: 10.1007/s005990050080]

77 **Vijayvergiya R**, Agarwal N, Bahl A, Grover A, Singh M, Sharma M, Khullar M. Association of Chlamydia pneumoniae and Helicobacter pylori infection with angiographically demonstrated coronary artery disease. *Int J Cardiol* 2006; **107**: 428-429 [PMID: 16503271 DOI: 10.1016/j.ijcard.2005.02.028]

78 **Franceschi F**, Niccoli G, Ferrante G, Gasbarrini A, Baldi A, Candelli M, Feroce F, Saulnier N, Conte M, Roccarina D, Lanza GA, Gasbarrini G, Gentiloni SN, Crea F. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. *Atherosclerosis* 2009; **202**: 535-542 [PMID: 18599062 DOI: 10.1016/j.atherosclerosis.2008.04.051]

79 **Cremonini F**, Gabrielli M, Gasbarrini G, Pola P, Gasbarrini A. The relationship between chronic H. pylori infection, CagA seropositivity and stroke: meta-analysis. *Atherosclerosis* 2004; **173**: 253-259 [PMID: 15064099 DOI: 10.1016/j.atherosclerosis.2003.12.012]

80 **Goyal P**, Kalek SC, Chaudhry R, Chauhan S, Shah N. Association of common chronic infections with coronary artery disease in patients without any conventional risk factors. *Indian J Med Res* 2007; **125**: 129-136 [PMID: 17431281]

81 **Vijayvergiya R**. Association of infection with coronary artery disease. *Indian J Med Res* 2007; **125**: 112-114 [PMID: 17431279]

82 **Al-Nozha MM**, Khalil MZ, Al-Mofleh IA, Al-Ghamdi AS. Lack of association of coronary artery disease with H.pylori infection. *Saudi Med J* 2003; **24**: 1370-1373 [PMID: 14710286]

83 **Kanbay M**, Gür G, Yücel M, Yilmaz U, Muderrisoglu H. Helicobacter pylori seroprevalence in patients with coronary artery disease. *Dig Dis Sci* 2005; **50**: 2071-2074 [PMID: 16240217 DOI: 10.1007/s10620-005-3009-7]

84 **Basili S**, Vieri M, Di Lecce VN, Maccioni D, Marmifero M, Paradiso M, Labbadia G, Spada S, Cordova C, Alessandri C. Association between histological diagnosis of Helicobacter pylori and coronary heart disease: results of a retrospective study. *Clin Ter* 1998; **149**: 413-417 [PMID: 10100402]

85 **Bielański W**. Epidemiological study on Helicobacter pylori infection and extragastroduodenal disorders in Polish population. *J Physiol Pharmacol* 1999; **50**: 723-733 [PMID: 10695554]

86 **Quinn MJ**, Foley JB, Mulvihill NT, Lee J, Crean PA, Walsh MJ, O'Morain CA. Helicobacter pylori serology in patients with angiographically documented coronary artery disease. *Am J Cardiol* 1999; **83**: 1664-1666, A6 [PMID: 10392873 DOI: 10.1016/S0002-9149(99)00175-7]

87 **Haider AW**, Wilson PW, Larson MG, Evans JC, Michelson EL, Wolf PA, O'Donnell CJ, Levy D. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. *J Am Coll Cardiol* 2002; **40**: 1408-1413 [PMID: 12392829 DOI: 10.1016/S0735-1097(02)02272-6]

88 **Coles KA**, Knuiman MW, Plant AJ, Riley TV, Smith DW, Divitini ML. A prospective study of infection and cardiovascular diseases: the Busselton Health Study. *Eur J Cardiovasc Prev Rehabil* 2003; **10**: 278-282 [PMID: 14555883 DOI: 10.1097/00149831-200308000-00010]

89 **Danesh J**. Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies. *Am Heart J* 1999; **138**: S434-S437 [PMID:

10539843]
90 **Schiele F**, Batur MK, Seronde MF, Meneveau N, Sewoke P, Bassignot A, Couetdic G, Caulfield F, Bassand JP. Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent implantation: an angiographic and intravascular ultrasound study. *Heart* 2001; **85**: 304-311 [PMID: 11179272 DOI: 10.1136/heart.85.3.304]
91 **Limnell V**, Pasternack R, Karjalainen J, Virtanen V, Lehtimäki T, Aittoniemi J. Seropositivity for Helicobacter pylori antibodies is associated with lower occurrence of venous bypass graft occlusion. *Scand J Infect Dis* 2004; **36**: 601-603 [PMID: 15370672 DOI: 10.1080/00365540410016753]
92 **Stone AF**, Risley P, Markus HS, Butland BK, Strachan DP, Elwood PC, Mendall MA. Ischaemic heart disease and Cag A strains of Helicobacter pylori in the Caerphilly heart disease study. *Heart* 2001; **86**: 506-509 [PMID: 11602541 DOI: 10.1136/heart.86.5.506]
93 **Rasmi Y**, Raeisi S, Seyyed Mohammadzad MH. Association of inflammation and cytotoxin-associated gene a positive strains of helicobacter pylori in cardiac syndrome x. *Helicobacter* 2012; **17**: 116-120 [PMID: 22404441]
94 **Lanza GA**, Sestito A, Cammarota G, Grillo RL, Vecile E, Cianci R, Speziale D, Dobrina A, Maseri A, Crea F. Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. *Am J Cardiol* 2004; **94**: 40-44 [PMID: 15219506 DOI: 10.1016/j.amjcard.2004.03.027]
95 **Danesh J**, Youngman L, Clark S, Parish S, Peto R, Collins R. Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. *BMJ* 1999; **319**: 1157-1162 [PMID: 10541503 DOI: 10.1136/bmj.319.7218.1157]
96 **Alkout AM**, Ramsay EJ, Mackenzie DA, Weir DM, Bentley AJ, Elton RA, Sutherland S, Busuttil A, Blackwell CC. Quantitative assessment of IgG antibodies to Helicobacter pylori and outcome of ischaemic heart disease. *FEMS Immunol Med Microbiol* 2000; **29**: 271-274 [PMID: 11118907 DOI: 10.1111/j.1574-695X.2000.tb01533.x]
97 **Kahan T**, Lundman P, Olsson G, Wendt M. Greater than normal prevalence of seropositivity for Helicobacter pylori among patients who have suffered myocardial infarction. *Coron Artery Dis* 2000; **11**: 523-526 [PMID: 11023239 DOI: 10.1097/00019501-200010000-00002]
98 **Kinjo K**, Sato H, Sato H, Shiotani I, Kurotobi T, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, Sasaki T, Kohama A, Abe Y, Morita H, Kubo M, Takeda H, Hori M. Prevalence of Helicobacter pylori infection and its link to coronary risk factors in Japanese patients with acute myocardial infarction. *Circ J* 2002; **66**: 805-810 [PMID: 12224816 DOI: 10.1253/circj.66.805]
99 **Fraser AG**, Scragg RK, Cox B, Jackson RT. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. *Intern Med J* 2003; **33**: 267-272 [PMID: 12823670]
100 **Zhu J**, Quyyumi AA, Muhlestein JB, Nieto FJ, Horne BD, Zalles-Ganley A, Anderson JL, Epstein SE. Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. *Am J Cardiol* 2002; **89**: 155-158 [DOI: 10.1016/S0002-9149(01)02192-0]
101 **Murray LJ**, Bamford KB, Kee F, McMaster D, Cambien F, Dallongeville J, Evans A. Infection with virulent strains of Helicobacter pylori is not associated with ischaemic heart disease: evidence from a population-based case-control study of myocardial infarction. *Atherosclerosis* 2000; **149**: 379-385 [PMID: 10729388 DOI: 10.1016/S0021-9150(99)00325-1]
102 **Pellicano R**, Parravicini PP, Bigi R, Gandolfo N, Aruta E, Gai V, Figura N, Angelino P, Rizzetto M, Ponzetto A. Infection by Helicobacter pylori and acute myocardial infarction. Do cytotoxic strains make a difference? *New Microbiol* 2002; **25**: 315-321 [PMID: 12173773]
103 **Gabrielli M**, Santoliquido A, Cremonini F, Cicconi V, Candelli M, Serricchio M, Tondi P, Pola R, Gasbarrini G, Pola P, Gasbarrini A. CagA-positive cytotoxic H. pylori strains as a link between plaque instability and atherosclerotic stroke. *Eur Heart J* 2004; **25**: 64-68 [PMID: 14683744 DOI: 10.1016/j.ehj.2003.10.004]
104 **De Bastiani R**, Gabrielli M, Ubaldi E, Benedetto E, Sanna G, Cottone C, Candelli M, Zocco MA, Saulnier N, Santoliquido A, Papaleo P, Gasbarrini G, Gasbarrini A. High prevalence of Cag-A positive H. pylori strains in ischemic stroke: a primary care multicenter study. *Helicobacter* 2008; **13**: 274-277 [PMID: 18665936 DOI: 10.1111/j.1523-5378.2008.00610.x]
105 **Huang B**, Chen Y, Xie Q, Lin G, Wu Y, Feng Y, Li J, Zhuo Y, Zhang P. CagA-positive Helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease. *Dig Dis Sci* 2011; **56**: 109-114 [PMID: 20503072 DOI: 10.1007/s10620-010-1274-6]
106 **Koenig W**, Rothenbacher D, Hoffmeister A, Miller M, Bode G, Adler G, Hombach V, März W, Pepys MB, Brenner H. Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. *Circulation* 1999; **100**: 2326-2331 [PMID: 10587336 DOI: 10.1161/01.CIR.100.23.2326]
107 **Whincup P**, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Hawkey C, Atherton J. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. *Circulation* 2000; **101**: 1647-1652 [PMID: 10758045 DOI: 10.1161/01.CIR.101.14.1647]
108 **Elkind MS**. Inflammatory mechanisms of stroke. *Stroke* 2010; **41**: S3-S8 [PMID: 20876499]
109 **Markus HS**, Mendall MA. Helicobacter pylori infection: a risk factor for ischaemic cerebrovascular disease and carotid atheroma. *J Neurol Neurosurg Psychiatry* 1998; **64**: 104-107 [PMID: 9436737 DOI: 10.1136/jnnp.64.1.104]
110 **Grau AJ**, Buggle F, Lichy C, Brandt T, Becher H, Rudi J. Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin. *J Neurol Sci* 2001; **186**: 1-5 [PMID: 11412864]
111 **Elkind MS**, Luna JM, Moon YP, Boden-Albala B, Liu KM, Spitalnik S, Rundek T, Sacco RL, Paik MC. Infectious burden and carotid plaque thickness: the northern Manhattan study. *Stroke* 2010; **41**: e117-e122 [PMID: 20075350 DOI: 10.1161/STROKEAHA]
112 **Huang WS**, Tseng CH, Lin CL, Tsai CH, Kao CH. Helicobacter pylori infection increases subsequent ischemic stroke risk: a nationwide population-based retrospective cohort study. *QJM* 2014; **107**: 969-975 [PMID: 24890556]
113 **Diomedi M**, Pietroiusti A, Silvestrini M, Rizzato B, Cupini LM, Ferrante F, Magrini A, Bergamaschi A, Galante A, Bernardi G. CagA-positive Helicobacter pylori strains may influence the natural history of atherosclerotic stroke. *Neurology* 2004; **63**: 800-804 [PMID: 15365126 DOI: 10.1212/01.WNL.0000138025.82419.80]
114 **Pietroiusti A**, Diomedi M, Silvestrini M, Cupini LM, Luzzi I, Gomez-Miguel MJ, Bergamaschi A, Magrini A, Carrabs T, Vellini M, Galante A. Cytotoxin-associated gene-A--positive Helicobacter pylori strains are associated with atherosclerotic stroke. *Circulation* 2002; **106**: 580-584 [PMID: 12147540 DOI: 10.1161/01.CIR.0000023894.10871.2F]
115 **Whincup PH**, Mendall MA, Perry IJ, Strachan DP, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. *Heart* 1996; **75**: 568-572 [PMID: 8697158 DOI: 10.1136/hrt.75.6.568]
116 **Heuschmann PU**, Neureiter D, Gesslein M, Craiovan B, Maass M, Faller G, Beck G, Neundoerfer B, Kolominsky-Rabas PL. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: Results from a population-based case-control study. *Stroke* 2001; **32**: 2253-2258 [PMID: 11588309 DOI: 10.1161/hs1001.097096]
117 **Bloemenkamp DG**, van den Bosch MA, Mali WP, Tanis BC, Rosendaal FR, Kemmeren JM, Algra A, Visseren FL, van der Graaf Y. Novel risk factors for peripheral arterial disease in young women. *Am J Med* 2002; **113**: 462-467 [PMID: 12427494 DOI: 10.1016/S0002-9343(02)01258-5]
118 **Bloemenkamp DG**, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, Algra A, Ossewaarde JM, Visseren FL,

van Loon AM, van der Graaf Y. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. *Atherosclerosis* 2002; **163**: 149-156 [PMID: 12048133 DOI: 10.1016/S0021-9150(01)00761-4]

119 **Sawayama Y**, Hamada M, Otaguro S, Maeda S, Ohnishi H, Fujimoto Y, Taira Y, Hayashi J. Chronic Helicobacter pylori infection is associated with peripheral arterial disease. *J Infect Chemother* 2008; **14**: 250-254 [PMID: 18574664 DOI: 10.1007/s10156-008-0613-4]

P- Reviewer: Konturek PC, Shimatani T, Slomiany BL, Tosetti C
S- Editor: Ma YJ **L- Editor**: A **E- Editor**: Lu YJ

Published by **Baishideng Publishing Group Inc**
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
http://www.wjgnet.com

© 2015 Baishideng Publishing Group Inc. All rights reserved.